Foresite Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystHongShan Capital GroupLAVLilly Asia VenturesOrbiMed+2 more
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)Stephen Mitchener(Executive Officer)Michael Mason(Executive Officer)
Co-investorsAvoro Capital AdvisorsHEALTHCARE ROYALTY PARTNERS
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.